Sotorasib Edges Closer to Approval
- PMID: 33547148
- DOI: 10.1158/2159-8290.CD-NB2021-0309
Sotorasib Edges Closer to Approval
Abstract
The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
©2021 American Association for Cancer Research.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
